Regulatory Progress in Key Markets
Positive feedback from major regulatory agencies, including China's NMPA and the U.K.'s MHRA, agreeing to accept priority and conditional marketing authorization applications based on interim analysis results from the Phase III DRAGON trial.
Successful Funding Initiatives
Completed a $50 million registered direct offering and a $125 million private placement, with the potential for an additional $165 million upon full warrant exercise, resulting in a strong cash position of $275.6 million.
Advancement in Clinical Trials
Completed enrollment of the Phase III PHOENIX trial for GA with 530 subjects and the Phase III DRAGON trial for Stargardt's disease, with ongoing enrollment in the DRAGON II trial.